Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer (Triple-B)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01898117 |
Recruitment Status :
Recruiting
First Posted : July 12, 2013
Last Update Posted : March 22, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer | Drug: Carbo/cyclo Drug: Carbo/cyclo + atezolizumab Drug: Paclitaxel Drug: Paclitaxel + Atezolizumab | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 304 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer |
Actual Study Start Date : | July 2013 |
Estimated Primary Completion Date : | December 2024 |
Estimated Study Completion Date : | December 2030 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Carbo/cyclo
Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks
|
Drug: Carbo/cyclo
Other Names:
|
Active Comparator: Carbo/cyclo + Atezolizumab
Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 atezolizumab 840 mg d1,15 Q 4 weeks
|
Drug: Carbo/cyclo + atezolizumab
Other Names:
|
Active Comparator: Paclitaxel
Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks
|
Drug: Paclitaxel |
Active Comparator: Paclitaxel + atezolizumab
Paclitaxel 90 mg/m2 d1, 8, 15 atezolizumab 840 mg d1,15 Q 4 weeks
|
Drug: Paclitaxel + Atezolizumab
Other Names:
|
- Validate the BRCA-like test [ Time Frame: assessed up to 120 months ]Validate the BRCA-like test in predicting differential PFS with first line alkylating and platinum agents when compared to paclitaxel in TNBC
- Improvement of objective response by adding atezolizumab [ Time Frame: assessed up to 120 months ]Determine whether atezolizumab added to first line palliative chemotherapy improves objective response in TNBC
- Define predictive biomarkers for objective response gain [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months ]Define predictive biomarkers for objective response gain of the addition of atezolizumab to first line chemotherapy; e.g PD-L1, intratumoral CD8, TILs and pre-treatment LDH
- Define predictive biomarkers for PFS gain [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months ]Define predictive biomarkers for PFS gain of carboplatin-cyclophosphamide or paclitaxel chemotherapy
- Determine PFS in BRCA like TNBC [ Time Frame: From date of randomization until date of first documented progression or date of death, which ever comes first, assessed up to 120 months ]Determine whether an alkylating platinum regimen is more effective then paclitaxel regarding PFS in BRCA like TNBC
- Determine PFS in non BRCA like TNBC [ Time Frame: From date of randomization until date of first documented progression or date of death, which ever comes first, assessed up to 120 months ]Determine whether paclitaxel is more effective then an alkylating platinum regimen regarding PFS in non BRCA like TNBC
- Overall survival (OS) [ Time Frame: assessed up to 120 months ]Evaluation of overall survival (OS) for all (sub)group comparisons as pre-specified for PFS
- Toxicity of all study regimens [ Time Frame: Assessed at 1 year ]Adverse events will be graded according to NCI Common Toxicity Criteria version 4.03
- Determine PFS in cross over [ Time Frame: At 6 and 12 months and up to 120 months ]Determine the PFS and objective response after cross over to the other chemotherapy regimen with atezolizumab
- Determine PFS in TNBC molecular subtypes [ Time Frame: Assessed up to 120 months ]Determine whether TNBC molecular subtypes as defined by gene expression are predictive for differential PFS benefit of atezolizumab added to first line chemotherapy

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Metastasized or locally advanced incurable triple negative breast cancer; patients with stage IV at diagnosis are eligible as well. If the primary lesion is the only measurable lesion according to RECIST criteria, every locoregional treatment must be mentioned to the investigators.
- Histologically confirmed triple negative breast cancer (ER: < 10% nuclear staining of tumor cells on IHC; HER2: either score 0 or 1 at immunohistochemistry or negative at in situ hybridization [CISH or FISH] in case of score 2 or 3 on IHC)
- Histological confirmation of triple negative breast cancer of a metastatic lesion is recommended
- Histological or cytological confirmation of metastatic breast cancer is required in case of normal CA 15.3 levels
- Primary tumor or metastasis tissue (10 x10 μm blank slides FFPE tumor material) sent to NKI-AVL for BRCA-like testing
- Pretreatment histological biopsy of a metastatic lesion for the translational research questions (tumor tissue from bone metastases cannot be used).
- No previous cytotoxic therapy for metastatic disease
- Disease-free interval of at least 12 months after completion of adjuvant paclitaxel or platinum compound therapy
- Disease-free interval of at least 6 months after completion of adjuvant docetaxel
- Measurable disease according to RECIST v1.1
- WHO performance status of 0 or 1
- Adequate bone marrow function: neutrophils ≥ 1.5 x 10E9 cells/l, platelets ≥100 x 10E9 cells/l, Hb ≥ 6.2 mmol/l.
- Normal liver function: bilirubin < 1.5 x upper limit of the normal range (ULN); alkaline phosphatase < 2.5 x ULN (< 5 x ULN in case of liver metastases, and < 7 x ULN in case of bone metastases); transaminases (ASAT/ALAT) < 2.5 x ULN (and < 5 x ULN in case of liver metastases).
-
Normal renal function:
> calculated (Cockcroft-Gault) or measured creatinine clearance > 50 mL/min
- INR < 1.5 and APTT normal, unless patient is on stable anti-coagulant treatment for at least two weeks with a low molecular weight heparin or coumarin, then an INR within the target range (usually between 2 and 3) is allowed.
- Written informed consent
Exclusion Criteria:
- Receptor conversion to hormone receptor positive (defined as >= 10% positive ER or PgR tumor cells) or HER2 positive
- Another cancer except basal-cell carcinoma of the skin or in situ cervical cancer within the previous 5 years
- Other antitumor therapy within the previous 21 days
- Radiotherapy with palliative intent within the previous 7 days before randomization.
- Known CNS disease except for treated brain metastases.
- Uncontrolled serious medical or psychiatric illness
- Pre-existing peripheral neuropathy > grade 1 (NCI-CTC AE (version 4.03)) at inclusion
- Severe infection within 4 weeks prior to randomization
- received antibiotocs within 2 weeks prior to cycle 1, day 1
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for major surgical procedure during the course of the study
- New York Heart Association Class II or greater congestive heart failure. LVEF by MUGA, ultrasound or MRI must be ≥ 50% and should be performed within 4 weeks prior to randomization if cardiac failure is suspected.
- History of myocardial infarction or unstable angina within 6 months prior to randomization
- History of myocardial infarction or unstable angina or unstable arrhytmias within 3 months prior to randomization
futher criteria, see protocol

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01898117
Contact: Sabine C Linn, Prof. MD | +3120512 ext 2951 | s.linn@nki.nl | |
Contact: Ingrid A. Mandjes, MSc | +3120512 ext 2880 | i.mandjes@nki.nl |

Principal Investigator: | Rianne Oosterkamp, MD | MC Haaglanden | |
Principal Investigator: | Marleen Kok, MD | NKI-AvL |
Responsible Party: | The Netherlands Cancer Institute |
ClinicalTrials.gov Identifier: | NCT01898117 |
Other Study ID Numbers: |
M13TNB 2013-001484-23 ( EudraCT Number ) NL44403.031.13 ( Other Identifier: CCMO ) |
First Posted: | July 12, 2013 Key Record Dates |
Last Update Posted: | March 22, 2022 |
Last Verified: | March 2022 |
Triple negative Metastatic |
Breast Neoplasms Triple Negative Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel Albumin-Bound Paclitaxel Cyclophosphamide Carboplatin Atezolizumab Antibodies, Monoclonal Antineoplastic Agents, Phytogenic |
Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Myeloablative Agonists |